9 METERS BIOPHARMA, INC.【NMTRQ】
| Dec 31,
2016 | Dec 31,
2017 | Dec 31,
2018 | Dec 31,
2019 | Dec 31,
2020 | Dec 31,
2021 | Dec 31,
2022 |
|---|
| Net loss | -6 | -8 | -24,162,279 | -27,048,808 | -61,496,489 | -36,779,400 | -43,766,415 |
|---|
| Share-based compensation | 1 | 1 | 4 | 3 | 5 | 2 | 4 |
|---|
| Amortization of debt discount | - | - | 3 | 1 | 2 | 43,983 | 2 |
|---|
| Depreciation | - | - | 19,555 | 21,607 | 18,491 | 7,573 | 8,523 |
|---|
| Noncash Research And Development In Process | - | - | - | - | - | 3 | - |
|---|
| Change in fair value of derivative liability | - | - | -50,000 | -873,000 | -771,000 | -7,000 | -437,000 |
|---|
| Non-Cash Milestone Fees | - | - | - | - | - | - | 500,000 |
|---|
| Loss on extinguishment of convertible note payable | - | - | - | - | - | - | -20,645 |
|---|
| Prepaid expenses and other assets | - | - | 298,724 | 50,145 | 445,535 | 2 | 368,669 |
|---|
| Accounts payable | -1 | 0 | 86,412 | 124,973 | -2,465,074 | 1 | 3 |
|---|
| Accrued expenses and other liabilities | - | - | - | - | - | - | -1,588,529 |
|---|
| Accrued interest | - | - | - | -101,624 | 488 | -488 | - |
|---|
| Net cash used in operating activities | - | -4 | -15,169,330 | -17,967,992 | -19,409,786 | -29,478,275 | -37,243,217 |
|---|
| Purchase of property and equipment | - | - | 13,943 | 11,934 | 2,543 | 12,476 | 2,842 |
|---|
| Purchase of in-process research and development, net of assets acquired | - | - | - | - | 3 | 2 | - |
|---|
| Maturity of restricted deposit | - | - | - | - | - | 75,000 | - |
|---|
| Net cash used in investing activities | - | - | -13,943 | -11,934 | -3,186,997 | -2,430,641 | -2,842 |
|---|
| Proceeds from Notes Payable | - | - | 3 | 5 | 3 | - | 21 |
|---|
| Payments of debt issuance costs | 0 | - | 50,000 | 57,000 | 23,000 | - | 1 |
|---|
| Payments of convertible notes | - | - | - | - | - | 58,199 | - |
|---|
| Proceeds from Issuance of Common Stock | 1 | 0 | 18 | 21 | 37 | 35 | - |
|---|
| Proceeds from Stock Options Exercised | - | - | 182,428 | 30,064 | - | 346,961 | - |
|---|
| Proceeds from Warrant Exercises | - | - | 928,178 | - | 3 | 9 | - |
|---|
| Payment of offering costs | 1 | - | 1 | 1 | 6 | 3 | - |
|---|
| Net cash provided by financing activities | - | 3 | 21 | 17 | 56 | 41 | 20 |
|---|
| Net (decrease) increase in cash, cash equivalents and restricted cash | - | - | - | -1,135,968 | 33 | 9 | -17,334,353 |
|---|
| Cash paid during the year for interest | 0 | 0 | 280,287 | 874,203 | 62,912 | 569 | 835,038 |
|---|
| Stock Issued | - | - | 9 | - | 5 | - | 105,342 |
|---|
| Noncash Addition Of Derivative Liability | - | - | - | - | 370,000 | - | 2 |
|---|